How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
GEN - Genetic Engineering and Biotechnology News2d
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company ...
STAT5d
Zealand’s obesity strategy and Immunovant’s curious development plan
For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular ...
GEN - Genetic Engineering and Biotechnology News7d
DMD Patient Dies After Treatment with Sarepta Gene Therapy
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...
Fierce Pharma7d
Sarepta reports one death after patient received DMD gene therapy Elevidys
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech ...
Sarepta plunges after death linked to Elevidys (update)
Sarepta Therapeutics (SRPT) stock drops 25% as the company reports a patient death linked to Elevidys, its gene therapy developed with Roche (RHHBY). Read more here.
STAT7d
Pharmalittle: We’re reading about pharma tariff worries, Wegovy and hair loss, and more
Drugmakers are urging the Trump administration and EU officials to exclude medical goods from expanding tariffs wars ...
American Association of Individual Investors9d
Which Is a Better Investment, PTC Therapeutics, Inc. or Sarepta Therapeutics, Inc. Stock?
Learn more about whether PTC Therapeutics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...
ETF Daily News15d
Charles Schwab Investment Management Inc. Raises Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Sarepta Therapeutics Trading Down 3.2 % SRPT stock opened at $99.69 on Tuesday. Sarepta Therapeutics, Inc. has a 1-year low of $98.82 and a 1-year high of $173.25. The company has a debt-to-equity ...